Subject: Immunization Products Funding
Date: Published: 5/15/92 (20 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    Technology:
    Immunization Products Funding

    SAN DIEGO -- Immune Response Corp. and Rhone-Poulenc Rorer
 Inc., a Collegeville, Pa., pharmaceutical concern, said they
 agreed to invest an additional $9 million each in their AIDS
 joint venture, Immunization Products Ltd., which is
 developing an HIV therapeutic vaccine.
    Including the new amounts, the partners will have put a
 total of $36 million in capital into the joint venture,
 Immune Response, a biopharmaceutical concern, said.  The
 vaccine is currently undergoing clinical trials.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]